DeviceTalks Podcast Network

Clostridium difficile or C. diff. is a growing crisis in the U.S. with over 29,000 deaths and 500,000 cases annually, according to the CDC. The disease, which CDC officials warned can kill people in less than 30 days, is characterized by severe diarrhea, fever, and loss of appetite. Sadly, many elderly and infirmed patients are among the most vulnerable.

Roseville, Minn.-based Rebiotix is one of a handful of companies looking to harness the human microbiome into a treatment for recurrent C. diff, which impacts about 20-30% of patients, where there are currently no approved drugs to treat patients with two or more recurrences. Rebiotix is currently in Phase 2 clinical trials for the treatment, which harnesses gut microbiota and turns them into therapies. The company hopes recurrent C. diff is just the 1st in a pipeline of treatments than can be derived from the microbiome.

On this episode of DeviceTalks we discuss C.diff with Reviotix CEO Lee Jones. What personal stories led her to this mission; How powerful the human microbiome will be in the future of combating disease and the differences between running a medtech company and a biotech company.

Clostridium difficile or C. diff. is a growing crisis in the U.S. with over 29,000 deaths and 500,000 cases annually, according to the CDC. The disease, which CDC officials warned can kill people in less than 30 days, is characterized by severe diarrhea, fever, and loss of appetite. Sadly, many elderly and infirmed patients are among the most vulnerable.

Roseville, Minn.-based Rebiotix is one of a handful of companies looking to harness the human microbiome into a treatment for recurrent C. diff, which impacts about 20-30% of patients, where there are currently no approved drugs to treat patients with two or more recurrences. Rebiotix is currently in Phase 2 clinical trials for the treatment, which harnesses gut microbiota and turns them into therapies. The company hopes recurrent C. diff is just the 1st in a pipeline of treatments than can be derived from the microbiome.

On this episode of DeviceTalks we discuss C.diff with Reviotix CEO Lee Jones. What personal stories led her to this mission; How powerful the human microbiome will be in the future of combating disease and the differences between running a medtech company and a biotech company.

For a man who took a private company from $17 million in sales to a $4.5 billion publicly traded juggernaut, John Brown is a remarkably humble man. However, he is, by all intents and purposes, the man who put Stryker on the map. Today, the Kalamazoo, Mich.-based medical device company nets nearly $10 billion in annual sales.

In this episode of DeviceTalks, recorded at the recent AdvaMed 2015 conference, Brown spoke to us about how he built such impressive results during his tenure at Stryker, including the lessons he learned along the way.

For a man who took a private company from $17 million in sales to a $4.5 billion publicly traded juggernaut, John Brown is a remarkably humble man. However, he is, by all intents and purposes, the man who put Stryker on the map. Today, the Kalamazoo, Mich.-based medical device company nets nearly $10 billion in annual sales.

In this episode of DeviceTalks, recorded at the recent AdvaMed 2015 conference, Brown spoke to us about how he built such impressive results during his tenure at Stryker, including the lessons he learned along the way.

Big things sometimes come in small packages. For Sirtex Medical, the big thing comes in a really small package.

The Australian medical device company’s flagship product - the SIR-sphere - is made up of 30 to 60 million microspheres about the size of a grain of sand, which are injected into the hepatic artery and flow into the liver where they kill tumors from the inside.

In this episode of DeviceTalks, MassDevice.com publisher Brian Johnson talks with Mangano about the company, the learning curve he had of moving from a traditional medical device company to an oncology company and why the cancer market may be ripe for other medtech companies to enter.

Big things sometimes come in small packages. For Sirtex Medical, the big thing comes in a really small package.

The Australian medical device company’s flagship product - the SIR-sphere - is made up of 30 to 60 million microspheres about the size of a grain of sand, which are injected into the hepatic artery and flow into the liver where they kill tumors from the inside.

In this episode of DeviceTalks, MassDevice.com publisher Brian Johnson talks with Mangano about the company, the learning curve he had of moving from a traditional medical device company to an oncology company and why the cancer market may be ripe for other medtech companies to enter.

Colon cancer is one of the most preventable cancers, yet it is also one of the deadliest forms of the disease. In this episode, we speak with Graham Lidgard, the Chief Science Officer, Senior Vice President of Research and Development at Exact Sciences, a Wisc. -based company that has developed a non invasive test to detect colorectal cancer without having to undergo a colonoscopy. We talk to Graham about the Cologuard test and his 40 year career developing breakthrough medical technology.

Colon cancer is one of the most preventable cancers, yet it is also one of the deadliest forms of the disease. In this episode, we speak with Graham Lidgard, the Chief Science Officer, Senior Vice President of Research and Development at Exact Sciences, a Wisc. -based company that has developed a non invasive test to detect colorectal cancer without having to undergo a colonoscopy. We talk to Graham about the Cologuard test and his 40 year career developing breakthrough medical technology.

Before Stephen Ubl departed for a job as the chief lobbyist for the pharmaceutical industry, medtech's main man in Washington D.C. sat down with us to reflect on his time as CEO of AdvaMed. In this episode of DeviceTalks, we go deep into Ubl's background, the fights over the medical device tax, forging a new partnership with the FDA and more.

Before Stephen Ubl departed for a job as the chief lobbyist for the pharmaceutical industry, medtech's main man in Washington D.C. sat down with us to reflect on his time as CEO of AdvaMed. In this episode of DeviceTalks, we go deep into Ubl's background, the fights over the medical device tax, forging a new partnership with the FDA and more.